NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/alto-neuroscience-inc-loss-submission-form/?id=166908&from=3 CLASS PERIOD: ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO†); and/or (ii) securities between February 2, 2024 and October 22, 2024. Alto describes itself as a "clinical-stage biopharmaceutical company in the U.S.†For more infor. ...

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquir ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder ...

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...

**Alto Neuroscience 电话会议纪要关键要点** **公司及行业** * Alto Neuroscience是一家临床阶段生物制药公司 专注于通过生物标志物引导的药物开发开创精准精神病学[2] * 公司利用专有平台结合脑电图(EEG) 认知评估和可穿戴设备数据 将合适的患者与合适的治疗相匹配[2] * 行业背景是精神病学领域缺乏精准性 当前药物开发和部署基于捕获大量临床和生物学异质性的疾病定义 导致药物开发普遍失败 即使成功效应量也较小[5] **核心平台与技术** * 公司平台的核心是使用生物标志物(如EEG 认知测试 可穿戴设备数据)作为可测量的大脑功能属性来指导药物开发和部署[5] * 生物标志物用于选择最可能应答的患者 在如抑郁症的广泛人群中 约30%至50%符合任何给定生物标志物[6] * 生物标志物也用作结果指标和过程测量 减少对晚期试验显示疗效的依赖 并能在早期显示正确的靶点参与[6][7] * 公司拥有一个经前瞻性多次复制的安慰剂预测生物标志物 可用于预测药物应答 并希望其不预测安慰剂应答 从而在更可能对药物应答且更不可能对安慰剂应答的人群中推进项目[9][10] **产品管线与临床项目** **ALTO 207 (治疗抵抗性抑郁症)** * ALTO 207是一种普拉克索和昂丹司琼的复方制剂 旨在直接刺激多巴胺受体(D2/D3) 用于治疗抵抗性抑郁症(TRD)[12][13] * 其治疗原理是基于生物标志物发现TRD患者存在更低的多巴胺水平 而该复方制剂可减轻普拉克索引起的恶心呕吐副作用(主要副作用) 同时不减低抗抑郁效果[13] * 来自Chase Therapeutics的2A期研究显示Cohen‘s D效应量为1.1 药物与安慰剂差异超过8分 而可治疗抑郁症的效应量通常为0.3(2-3分) 此效应量是其三倍[13][14] * 牛津大学一项研究使用普拉克索单药在重度TRD人群(中位病程10年 4种药物失败)中显示Cohen’s D效应量为0.9 但20%的患者因副作用脱落(安慰剂组为5%)[14] * 复方疗法允许加快5倍给药速度 Chase能在约一周内达到比牛津研究更高的治疗剂量[14] * 2B期试验将预先定义疗效和耐受性生物标志物 其结果可能直接成为注册申报资料的一部分 并指导后续3期试验的富集策略[16] **ALTO 101 (精神分裂症相关认知障碍 CIAS)** * ALTO 101是一种PDE4抑制剂 通过增加环磷酸腺苷(cAMP)来改善可塑性和认知 并非主要利用其抗炎作用[20] * 公司将其从口服重新配方为透皮贴剂 减缓药物吸收 从而消除了不良反应(PDE4副作用) 在进行的2期试验中耐受性良好[21] * 公司发现并独立复制了theta ITC(对感觉刺激的节律性反应)作为CIAS的EEG生物标志物 它是疾病最稳健的标志物 与认知相关性最佳 并已将其作为概念验证试验的主要结局指标[18][19][20] * 在1期研究中 药物对该EEG生物标志物呈剂量依赖性效应 在健康人中单次给药即可改善认知 且认知改善与EEG生物标志物改善相关[22] * 当前2期概念验证试验采用交叉设计 治疗10天 主要结局是EEG生物标志物(机制层面的Go/No-Go) 次要结局包括认知[22][23] **ALTO 300 (重度抑郁症 MDD)** * ALTO 300是阿戈美拉汀(欧洲和澳大利亚已批准的抗抑郁药) 在美国作为新化学实体开发 采用辅助治疗策略用于一线治疗失败的MDD患者(占人群大多数)[26][27] * 公司利用EEG和机器学习方法发现了一个可预测更好应答且不预测更高安慰剂应答的生物标志物 该标志物描述了约50%的MDD人群[27] * 2B期试验主要招募生物标志物阳性患者(主要效力人群) 并包含一小部分阴性人群以探索富集问题 预计明年年中读出结果[28] * 公司进行了盲态病例审查和中期分析 剔除了存在“专业患者”执行风险的站点数据 结果显示支持药物效应的信号 研究继续推进[29] **ALTO 100 (双相抑郁)** * ALTO 100在双相抑郁中推进 该领域可用治疗极少(主要为副作用负担重的抗精神病药)[34] * 先前在MDD的研究中 辅助治疗人群(约占总样本30%)显示出Cohen‘s D为0.47的效应量 尽管未为显著性设计 但接近显著[33] * 该药物是一种新型神经可塑性增强剂 采用记忆测试生物标志物识别具有更显著神经可塑性缺陷和学习记忆缺陷的患者[34][35] * Wellcome Trust合作资助了约1200万美元 该研究作为2B期试验 预计明年下半年读出结果[34][35] **ALTO 203** * ALTO 203是一种H3反向激动剂 在单次给药药效学研究中显示可改善认知 增加清醒度 并改变EEG认知生物标志物[39] * 该生物标志物是FDA批准的ADHD测量指标 且该生物标志物可预测药物的更好认知效果[39] * 公司目前未利用现有资金推进该项目 优先关注更晚期项目 但该项目具有价值 存在合作或其他开发方式的潜在选择[40] **重要里程碑与投资者关注点** * 主要未来6-12个月里程碑 ALTO 300的2B期数据(明年年中) ALTO 100在双相抑郁的2B期数据(明年下半年) 以及ALTO 101在CIAS的概念验证试验结果(今年晚些时候读出)[28][35][20] * 公司管线拥有多个后期阶段项目 潜在催化事件集中在高临床需求领域[35] * 公司通过合作伙伴关系(如Wellcome Trust)获得非稀释性资金[34]